UK cost-effectiveness agency NICE has said that Eli Lilly’s Emgality can be made available through the NHS for migraine prevention, the second drug in the CGRP inhibitor class to achieve th
Novartis’ Aimovig (erenumab) has been approved by the European Medicines Agency (EMA) making it first self-administered, monthly migraine prevention jab available for adult patients in Euro